{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T16:28:17Z","timestamp":1786811297009,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07934-y","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:10:37Z","timestamp":1786763437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox"],"prefix":"10.1007","author":[{"given":"Aikaterini","family":"Damianaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-7004","authenticated-orcid":false,"given":"Emelina","family":"Stambolliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Iliakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggeliki","family":"Vakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Kalliakouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polykarpos Christos","family":"Patsalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Konstantinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Petras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"issue":"5","key":"7934_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4093\/dmj.2023.0067","volume":"47","author":"SH Suh","year":"2023","unstructured":"Suh SH, Kim SW. Dyslipidemia in patients with chronic kidney disease: an updated overview. Diabetes Metab J. 2023;47(5):612\u201329.","journal-title":"Diabetes Metab J"},{"issue":"6","key":"7934_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3904\/kjim.2025.099","volume":"40","author":"JY Kim","year":"2025","unstructured":"Kim JY, Chung SM, Kim NH. Managing dyslipidemia in chronic kidney disease: a comprehensive overview of evidence and recommendations. Korean J Intern Med. 2025;40(6):876\u201389.","journal-title":"Korean J Intern Med"},{"issue":"12","key":"7934_CR3","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1194\/jlr.P900003-JLR200","volume":"50","author":"DT Chan","year":"2009","unstructured":"Chan DT, Dogra GK, Irish AB, et al. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res. 2009;50(12):2524\u201331.","journal-title":"J Lipid Res"},{"key":"7934_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5478708","author":"M Gyur\u00e1szov\u00e1","year":"2020","unstructured":"Gyur\u00e1szov\u00e1 M, Gureck\u00e1 R, B\u00e1b\u00ed\u010dkov\u00e1 J, T\u00f3thov\u00e1 \u013d. Oxidative stress in the pathophysiology of kidney disease: implications for noninvasive monitoring and identification of biomarkers. Oxid Med Cell Longev. 2020. https:\/\/doi.org\/10.1155\/2020\/5478708.","journal-title":"Oxid Med Cell Longev"},{"key":"7934_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/nu11112809","author":"JA Navarro-Garc\u00eda","year":"2019","unstructured":"Navarro-Garc\u00eda JA, Rodr\u00edguez-S\u00e1nchez E, Aceves-Ripoll J, et al. Oxidative status before and after renal replacement therapy: differences between conventional high flux hemodialysis and on-line hemodiafiltration. Nutrients. 2019. https:\/\/doi.org\/10.3390\/nu11112809.","journal-title":"Nutrients"},{"issue":"9","key":"7934_CR6","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1093\/ndt\/gfp163","volume":"24","author":"R Rao","year":"2009","unstructured":"Rao R, Ansell D, Gilg JA, Davies SJ, Lamb EJ, Tomson CR. Effect of change in renal replacement therapy modality on laboratory variables: a cohort study from the UK Renal Registry. Nephrol Dial Transplant. 2009;24(9):2877\u201382.","journal-title":"Nephrol Dial Transplant"},{"issue":"9374","key":"7934_CR7","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024\u201331.","journal-title":"Lancet"},{"issue":"12","key":"7934_CR8","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","volume":"5","author":"H Holdaas","year":"2005","unstructured":"Holdaas H, Fellstr\u00f6m B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929\u201336.","journal-title":"Am J Transplant"},{"key":"7934_CR9","unstructured":"Lacount S, Tannock LR. Dyslipidemia in Chronic Kidney Disease. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, et al. editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright \u00a9 2000\u20132026. MDText.com, Inc.; 2000."},{"issue":"4s","key":"7934_CR10","first-page":"S117","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO. 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4s):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"6","key":"7934_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","volume":"49","author":"P Pavlakou","year":"2017","unstructured":"Pavlakou P, Liberopoulos E, Dounousi E, Elisaf M. PCSK9 in chronic kidney disease. Int Urol Nephrol. 2017;49(6):1015\u201324.","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"7934_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00228-025-03965-w","volume":"82","author":"T \u00c1bel","year":"2026","unstructured":"\u00c1bel T, Bencz\u00far B, Csajb\u00f3kn\u00e9 \u00c9C. Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. Eur J Clin Pharmacol. 2026;82(2):37.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"7934_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ndt\/gfy257","volume":"35","author":"LD Rasmussen","year":"2020","unstructured":"Rasmussen LD, Bottcher M, Ivarsen P, et al. Association between circulating proprotein convertase subtilisin\/kexin type 9 levels and prognosis in patients with severe chronic kidney disease. Nephrol Dial Transpl. 2020;35(4):632\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"7934_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2215\/CJN.01230122","volume":"17","author":"A Kheirkhah","year":"2022","unstructured":"Kheirkhah A, Lamina C, Kollerits B, et al. PCSK9 and cardiovascular disease in individuals with moderately decreased kidney function. Clin J Am Soc Nephrol. 2022;17(6):809\u201318.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"7934_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/bcp.70286","volume":"92","author":"B Bajorek","year":"2026","unstructured":"Bajorek B, Sawalha R, Liang Y, Ganesh L, Afifi M. Overcoming barriers to adherence through innovative injectable medications: a systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use. Br J Clin Pharmacol. 2026;92(1):73\u2013108.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"7934_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157\u201372.","journal-title":"Circulation"},{"issue":"23","key":"7934_CR17","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","volume":"46","author":"K Marx-Sch\u00fctt","year":"2025","unstructured":"Marx-Sch\u00fctt K, Cherney DZI, Jankowski J, et al. Cardiovascular disease in chronic kidney disease. Eur Heart J. 2025;46(23):2148\u201360.","journal-title":"Eur Heart J"},{"issue":"6","key":"7934_CR18","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10741-019-09874-2","volume":"25","author":"S Azari","year":"2020","unstructured":"Azari S, Rezapour A, Omidi N, et al. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review. Heart Fail Rev. 2020;25(6):1077\u201388.","journal-title":"Heart Fail Rev"},{"key":"7934_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2026.120670","volume":"414","author":"BS Mansfield","year":"2026","unstructured":"Mansfield BS, Bene-Alhasan Y, Ballantyne CM, Raal FJ. The evolving therapeutic landscape of PCSK9 inhibition. Atherosclerosis. 2026;414:120670.","journal-title":"Atherosclerosis"},{"key":"7934_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf734","author":"HS Bhatia","year":"2025","unstructured":"Bhatia HS, Cuomo R, Ramsis M, Mahmud E, Taub P, Wilkinson MJ. Impact of PCSK9 inhibitors on lipoprotein(a) levels: a multi-center study. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf734.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"7934_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","volume":"3","author":"L Qi","year":"2023","unstructured":"Qi L, Liu D, Qu Y, et al. Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. JACC Asia. 2023;3(4):636\u201345.","journal-title":"JACC Asia"},{"issue":"11","key":"7934_CR22","doi-asserted-by":"publisher","first-page":"e033669","DOI":"10.1161\/JAHA.123.033669","volume":"13","author":"X Wang","year":"2024","unstructured":"Wang X, Qiu M, Cheng Z, et al. Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia. J Am Heart Assoc. 2024;13(11):e033669.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"7934_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cpdd.650","volume":"8","author":"E Lee","year":"2019","unstructured":"Lee E, Gibbs JP, Emery MG, et al. Influence of renal function on evolocumab exposure, pharmacodynamics, and safety. Clin Pharmacol Drug Dev. 2019;8(3):281\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"7934_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc. 2020;95(1):77\u201389.","journal-title":"Mayo Clin Proc"},{"key":"7934_CR25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000001006","author":"U Landmesser","year":"2026","unstructured":"Landmesser U, Ray KK, Raal FJ, et al. Inclisiran in patients with CKD: post hoc pooled analysis of three phase 3 trials. J Am Soc Nephrol. 2026. https:\/\/doi.org\/10.1681\/ASN.0000001006.","journal-title":"J Am Soc Nephrol"},{"issue":"40","key":"7934_CR26","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal F, Fourie N, Scott R, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272\u201380.","journal-title":"Eur Heart J"},{"issue":"9","key":"7934_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. JAMA Cardiol. 2024;9(9):800\u20137.","journal-title":"JAMA Cardiol"},{"key":"7934_CR28","first-page":"49","volume":"14","author":"CE Kosmas","year":"2022","unstructured":"Kosmas CE, Bousvarou MD, Sourlas A, et al. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia. Clin Pharmacol. 2022;14:49\u201359.","journal-title":"Clin Pharmacol"},{"key":"7934_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118189","volume":"188","author":"SS Tamehri Zadeh","year":"2025","unstructured":"Tamehri Zadeh SS, Toth PP, Shapiro MD, Surma S, Banach M. ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectives. Biomed Pharmacother. 2025;188:118189.","journal-title":"Biomed Pharmacother"},{"issue":"24","key":"7934_CR30","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in Patients with Refractory Hypercholesterolemia. N Engl J Med. 2020;383(24):2307\u201319.","journal-title":"N Engl J Med"},{"issue":"8","key":"7934_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"7934_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):913\u201325.","journal-title":"N Engl J Med"},{"key":"7934_CR33","unstructured":"Randomized AP. Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07271186"},{"issue":"6","key":"7934_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/CRD.0000000000000468","volume":"31","author":"M Gesner","year":"2023","unstructured":"Gesner M, Frishman WH. Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen. Cardiol Rev. 2023;31(6):325\u20139.","journal-title":"Cardiol Rev"},{"issue":"1","key":"7934_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11883-025-01290-2","volume":"27","author":"P Theofilis","year":"2025","unstructured":"Theofilis P, Vlachakis PK, Karakasis P, Kalaitzidis RG. Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk. Curr Atheroscler Rep. 2025;27(1):41.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"7934_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11883-025-01345-4","volume":"27","author":"S Tsimikas","year":"2025","unstructured":"Tsimikas S. Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease. Curr Atheroscler Rep. 2025;27(1):103.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"7934_CR37","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912.","journal-title":"N Engl J Med"},{"issue":"13","key":"7934_CR38","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","volume":"393","author":"BA Bergmark","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al. Targeting APOC3 with olezarsen in moderate hypertriglyceridemia. N Engl J Med. 2025;393(13):1279\u201391.","journal-title":"N Engl J Med"},{"issue":"19","key":"7934_CR39","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024;390(19):1770\u201380.","journal-title":"N Engl J Med"},{"issue":"14","key":"7934_CR40","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401\u201312.","journal-title":"Eur Heart J"},{"issue":"8","key":"7934_CR41","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care. 2016;39(8):1408\u201315.","journal-title":"Diabetes Care"},{"issue":"5","key":"7934_CR42","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438\u201347.","journal-title":"N Engl J Med"},{"key":"7934_CR43","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000968","author":"E Byambaa","year":"2025","unstructured":"Byambaa E, Roshanravan B, Berglund L. Lipoprotein(a) and CKD: insights into new therapeutic opportunities. Clin J Am Soc Nephrol. 2025. https:\/\/doi.org\/10.2215\/CJN.0000000968.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"7934_CR44","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019;73(23):2961\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"7934_CR45","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","volume":"41","author":"J Tu\u00f1\u00f3n","year":"2020","unstructured":"Tu\u00f1\u00f3n J, Steg PG, Bhatt DL, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020;41(42):4114\u201323.","journal-title":"Eur Heart J"},{"issue":"7","key":"7934_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100483","volume":"4","author":"C East","year":"2022","unstructured":"East C, Bass K, Mehta A, Rahimighazikalayed G, Zurawski S, Bottiglieri T. Alirocumab and lipid levels, inflammatory biomarkers, metabolomics, and safety in patients receiving maintenance dialysis: the ALIrocumab in DIALysis study (a phase 3 trial to evaluate the efficacy and safety of biweekly alirocumab in patients on a stable dialysis regimen). Kidney Med. 2022;4(7):100483.","journal-title":"Kidney Med"},{"issue":"3","key":"7934_CR47","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1111\/hdi.12839","volume":"24","author":"P Dousdampanis","year":"2020","unstructured":"Dousdampanis P, Assimakopoulos SF, Syrocosta I, Ntouvas I, Gkouias K, Trigka K. Alirocumab in a high cardiovascular risk patient on hemodialysis with liver abnormalities. Hemodial Int. 2020;24(3):E37\u20139.","journal-title":"Hemodial Int"},{"issue":"2","key":"7934_CR48","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.nefroe.2018.09.003","volume":"39","author":"S Gonz\u00e1lez Sanchidri\u00e1n","year":"2019","unstructured":"Gonz\u00e1lez Sanchidri\u00e1n S, Labrador G\u00f3mez PJ, Aguilar Aguilar JC, Davin Carrero E, Gallego Dom\u00ednguez S, G\u00f3mez-Martino Arroyo JR. Evolocumab for the treatment of heterozygous familial hypercholesterolemia in end-stage chronic kidney disease and dialysis. Nefrolog\u00eda (English Edition). 2019;39(2):218\u201320.","journal-title":"Nefrolog\u00eda (English Edition)"},{"issue":"4","key":"7934_CR49","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s13730-021-00605-x","volume":"10","author":"T Ishii","year":"2021","unstructured":"Ishii T, Ogura M, Nakamori H, et al. Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion. CEN Case Rep. 2021;10(4):592\u20137.","journal-title":"CEN Case Rep"},{"key":"7934_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11104","volume":"36","author":"L Ueberdiek","year":"2023","unstructured":"Ueberdiek L, Jehn U, Pavenst\u00e4dt H, Gebauer K, Reuter S. Novel therapeutic strategies for dyslipidemia: first report of inclisiran therapy in a kidney transplanted patient. Transpl Int. 2023;36:11104.","journal-title":"Transpl Int"},{"issue":"1","key":"7934_CR51","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12882-025-04347-1","volume":"26","author":"H Tang","year":"2025","unstructured":"Tang H, Li X, Wang F, et al. Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease. BMC Nephrol. 2025;26(1):472.","journal-title":"BMC Nephrol"},{"issue":"18","key":"7934_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.103897","volume":"30","author":"E Sani","year":"2025","unstructured":"Sani E, Rinaldi E, Lupo MG, et al. Treatment with inclisiran during peritoneal dialysis. JACC Case Rep. 2025;30(18):103897.","journal-title":"JACC Case Rep"},{"issue":"3","key":"7934_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S2213-8587(24)00313-9","volume":"13","author":"FJ Raal","year":"2025","unstructured":"Raal FJ, Mehta V, Kayikcioglu M, et al. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025;13(3):178\u201387.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"7934_CR54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/MOL.0000000000000981","volume":"36","author":"M Jean-Gilles","year":"2025","unstructured":"Jean-Gilles M, Gencer B. Therapeutic advances in the Lp(a) battle: what do we know and what are the most awaited novelties in the field? Curr Opin Lipidol. 2025;36(3):130\u20137.","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"7934_CR55","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"7934_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"42","key":"7934_CR57","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378.","journal-title":"Eur Heart J"},{"issue":"34","key":"7934_CR58","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"7934_CR59","unstructured":"Writing Committee M, Blumenthal RS, Morris PB, Gaudino M, ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA et al. \/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026."},{"issue":"3","key":"7934_CR60","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348.","journal-title":"N Engl J Med"},{"issue":"14","key":"7934_CR61","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407.","journal-title":"N Engl J Med"},{"issue":"9784","key":"7934_CR62","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"10","key":"7934_CR63","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"C Cholesterol Treatment Trialists","year":"2016","unstructured":"Cholesterol Treatment Trialists C, Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4(10):829\u201339.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07934-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T16:01:22Z","timestamp":1786809682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07934-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":63,"alternative-id":["7934"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07934-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}